‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.